SEC Filing · S-3
iBio, Inc.
IBIONASDAQEQUITYCurrent
SEC Filing
Company context
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
Current securities
Recent company filings
- 10-Q filingNov 10, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersOct 19, 2026
- 4 filingOct 15, 2026
- 4 filingOct 15, 2026
As-filed source
As filedOpen full document ↗